ConductScience.org, home

Paper36070540

A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).

Tanyi JL and 13 others. J Clin Oncol, 2023. Cited by 151 papers, by iCite.

Cite this record

ConductScience Library. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). Papers, record 36070540. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36070540

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
PubMed
Journal
J Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
151
iCite
Relative citation ratio, by iCite
19
iCite
Revised in PubMed
2026-01-27
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tanyi JLJanos Lhttps://orcid.org/0000-0002-5657-3698
2Randall LMLeslie Mhttps://orcid.org/0000-0003-3790-4858
3Chambers SKSetsuko K
4Butler KAKristina A
5Winer ISIra S
6Langstraat CLCarrie Lhttps://orcid.org/0000-0001-9361-8392
7Han ESErnest Shttps://orcid.org/0000-0001-6224-8544
8Vahrmeijer ALAlexander L
9Chon HSHye Sook
10Morgan MAMark Ahttps://orcid.org/0000-0001-5245-1709
11Powell MAMatthew Ahttps://orcid.org/0000-0002-1968-2772
12Tseng JHJill H
13Lopez ASAlexis S
14Wenham RMRobert Mhttps://orcid.org/0000-0002-6156-8885

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Folate Receptor 1Major topic
Ovarian NeoplasmsMajor topic
Humans
Female
Folic Acid
Molecular Imaging

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA022453NCI NIH HHSUnited StatesP30CA022453PubMedNIH RePORTER
P30 CA076292NCI NIH HHSUnited StatesP30CA076292PubMedNIH RePORTER

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03180307OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerDerived from the trialYesClinicalTrials.gov
NCT07469202CYTALUX Dose Extension StudyBackgroundClinicalTrials.gov
NCT07919509A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical ProceduresBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in37082670Ovarian cancer-targeted near-infrared fluorophores for fluorescence-guided surgery.https://conductscience.org/library/papers/37082670PubMed
Comment in37970599Pafolacianine, the magic wand of intraoperative imaging of folate-receptor positive ovarian cancer.https://conductscience.org/library/papers/37970599PubMed

Download CSV of comments and corrections

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19347791Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.J Invest Dermatol1997https://conductscience.org/library/papers/9347791PubMed
227306792A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.Clin Cancer Res2016https://conductscience.org/library/papers/27306792PubMed
326110901The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer.PLoS One2015https://conductscience.org/library/papers/26110901PubMed
415853442Chemotherapy-induced ovarian failure: manifestations and management.Drug Saf2005https://conductscience.org/library/papers/15853442PubMed
531851799Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.N Engl J Med2019https://conductscience.org/library/papers/31851799PubMed
615745749Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.Anal Biochem2005https://conductscience.org/library/papers/15745749PubMed
730345884Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.N Engl J Med2018https://conductscience.org/library/papers/30345884PubMed
821926976Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results.Nat Med2011https://conductscience.org/library/papers/21926976PubMed
99661918Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival.Am J Clin Pathol1998https://conductscience.org/library/papers/9661918PubMed
1019189636Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue.Anticancer Res2008https://conductscience.org/library/papers/19189636PubMed
1131216226Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.J Clin Oncol2019https://conductscience.org/library/papers/31216226PubMed
1231362825A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.Gynecol Oncol2019https://conductscience.org/library/papers/31362825PubMed
1326491562Comparison of Folate Receptor Targeted Optical Contrast Agents for Intraoperative Molecular Imaging.Int J Mol Imaging2015https://conductscience.org/library/papers/26491562PubMed
1426248049Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.PLoS One2015https://conductscience.org/library/papers/26248049PubMed
1518222534Folate receptor alpha as a tumor target in epithelial ovarian cancer.Gynecol Oncol2008https://conductscience.org/library/papers/18222534PubMed
1630254940Laparoscopy and Computed Tomography Imaging in Advanced Ovarian Tumors: A Roadmap for Prediction of Optimal Cytoreductive Surgery.Gynecol Minim Invasive Ther2018https://conductscience.org/library/papers/30254940PubMed
1731970129Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer.Obstet Gynecol Sci2020https://conductscience.org/library/papers/31970129PubMed
1834304313Time to Evolve Terminology from "Debulking" to Cytoreductive Surgery (CRS) in Ovarian Cancer.Ann Surg Oncol2021https://conductscience.org/library/papers/34304313PubMed
191234624Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.Natl Cancer Inst Monogr1975https://conductscience.org/library/papers/1234624PubMed
2019189349
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
Cancer2009https://conductscience.org/library/papers/19189349PubMed

See all 28 referencesDownload CSV of references

Cited by108

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.

PMIDTitleJournalYearIn PapersSource
42939681Validation of a Highly Specific Anti-Human Folate Receptor Alpha Single-Domain Antibody for Rapid Fluorescence-Guided Surgery of Ovarian and Lung Cancer.Biomolecules2026https://conductscience.org/library/papers/42939681PubMed
42922515Development and Optimization of 111In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma Resection.bioRxiv2026https://conductscience.org/library/papers/42922515PubMed
42883231Near-Infrared Fluorescence Probes for Fluorescence-Guided Surgery: Current Clinical Probes and Emerging Candidates.Molecules2026https://conductscience.org/library/papers/42883231PubMed
42881460Near-infrared fluorescence imaging for ureteral and sentinel lymph node mapping in gynecological minimally invasive surgery: a review of fluorophores and domestic laparoscopic systems.World J Surg Oncol2026https://conductscience.org/library/papers/42881460PubMed
42860479Beyond feasibility: an oncology-first framework for defining the role of robot-assisted surgery in ovarian cancer-patient selection, surgical adequacy, and conversion pathways.J Robot Surg2026https://conductscience.org/library/papers/42860479PubMed
42847075A Molecular Shielding Strategy to Develop Low Protein Binding, Renal Clearable Pan-Cancer Near-Infrared Probes.Adv Funct Mater2026https://conductscience.org/library/papers/42847075PubMed
42835385Delineating precise surgical resection areas: recent advances in NIR-II fluorescence imaging molecular probes.Front Oncol2026https://conductscience.org/library/papers/42835385PubMed
42826211A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer.Sci Adv2026https://conductscience.org/library/papers/42826211PubMed
42694955Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice.Int J Biol Sci2026https://conductscience.org/library/papers/42694955PubMed
42657301Progress in the Design and Clinical Application of Probes for Fluorescence-Guided Laparoscopic Surgery.Chem Biomed Imaging2026https://conductscience.org/library/papers/42657301PubMed
42559295Clinically accessible drug-based nano-assemblies with self-targeting ability for NIR-II fluorescence imaging-guided surgery in triple-negative breast cancer.Theranostics2026https://conductscience.org/library/papers/42559295PubMed
42373751Imaging the hallmarks of cancer.Nat Rev Cancer2026https://conductscience.org/library/papers/42373751PubMed
42355661Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery.J Clin Med2026https://conductscience.org/library/papers/42355661PubMed
42342710Multimodal imaging and artificial intelligence for response assessment to neoadjuvant therapy in breast cancer: a comprehensive review.NPJ Breast Cancer2026https://conductscience.org/library/papers/42342710PubMed
42281988Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression.Res Sq2026https://conductscience.org/library/papers/42281988PubMed
42198268Emerging Near-Infrared Targeted Imaging Pharmaceutics for Ovarian Cancer.Pharmaceutics2026https://conductscience.org/library/papers/42198268PubMed
42165837Advancements in Intraoperative Imaging for Enhanced Surgical Precision.Recent Results Cancer Res2026https://conductscience.org/library/papers/42165837PubMed
42081142Translational development of an SGLT2-targeted near-infrared contrast agent for intraoperative imaging of early-stage lung cancer.EJNMMI Res2026https://conductscience.org/library/papers/42081142PubMed
42052241In vivo Fluorescent Molecular Imaging Using Nanobodies Labeled with Next-Generation FNIR-Tag-Dyes.Res Sq2026https://conductscience.org/library/papers/42052241PubMed
42048455An Octopus probe for high-performance >1,300 nm NIR-II fluorescence molecular imaging of cancer.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/42048455PubMed

See all 108 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PAFOLACIANINECHEMBL4297412Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297412

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36070540

GET https://conductscience.org/api/papers/v1/36070540/references?page=2